Skip to main content
Cureus logoLink to Cureus
. 2020 Dec 30;12(12):e12389. doi: 10.7759/cureus.12389

The Prevalence and Association of Depression and Anxiety With Multiple Sclerosis in Riyadh, Saudi Arabia: A Cross-Sectional Study

Ali Bahathig 1, Mohammed A Alblowi 2, Amna A Alhilali 2,, Balqees S AlJasim 3, Manal Alhelow 3, Hamad Aldakheel 4, Nasser Alodayani 4, Narjes Hikri 3
Editors: Alexander Muacevic, John R Adler
PMCID: PMC7845751  PMID: 33532152

Abstract

Introduction

Multiple sclerosis (MS) is often associated with depression and anxiety, with no clear prevalence, and the relationship between them is not fully understood.

Methods

In a cross-sectional study of 365 multiple sclerosis patients selected through a random sampling method from the MS society of Riyadh, Saudi Arabia, we collected data by self-administered questionnaires - the Patient Health Questionnaire (PHQ-9) and the Generalized Anxiety Disorder (GAD-7) questionnaire - and analyzed by descriptive and analytical statistics.

Results

Approximately 51.1% of participants had moderate or severe anxiety and 64% of them had depression among community-based multiple sclerosis patients according to Generalized Anxiety Disorder (GAD-7) questionnaire, and according to the PHQ-9 Arabic version about 28.85% showed mild to moderate depression.

The MS patients aged 53 to over 60 years showed higher levels of mild anxiety (76.32%) and higher levels of depression ranging from mild to moderate (53.61%) (P = 0.001). While the MS patients younger than 53 years showed moderate to severe anxiety (60.71%) and depression levels (62.32%). In different age group bad health status (37.6%) was associated with a higher prevalence of depression levels (P =< 0.001) and people who were widowed (22.38%), divorced (26%), and separated (37.82%) had significant depression levels (P = 0.017). In terms of anxiety, 54.58% of females had anxiety (P = 0.005), more older people showed anxiety (43.17%) (P = 0.026), and people with a bad general health state (26.38%) had anxiety (P = <0.001).

Conclusion

Among different types of MS patients, anxiety is more prevalent in the elder group (76%) of people and depression is more prevalent in young patients (62%).

Keywords: anxiety, depression, neuropsychiatry, multiple sclerosis, quality of life, prevalence, saudi arabia

Introduction

The existence of a long-lasting incurable disease in a person’s life is a very traumatic event that requires special mental, social, and physical accommodation [1]. Multiple sclerosis (MS) is one of these major chronic illnesses.

MS is a neurodegenerative disease affecting the central nervous system (CNS) and leading to the damage of myelin and axons [2]. MS directly affects individuals in their productive time of life, limiting their work capacity, which results in major social and economic consequences [3].

The onset of MS is typically seen in individuals aged between 20 and 40 years. MS is seen in women two times more than in men [4].

MS appears as painless neuronal damage manifesting as vision impairment, double vision, limb weakness, unsteadiness of gait, and bowel or bladder symptoms [5]. The causative instigators for MS remain undetermined, but observational studies suggest genetic and environmental triggers influencing the pathophysiology of MS, which itself remains little understood, but is thought to be autoimmune in nature [6]. Diagnosis of MS is based on evaluation of disease dissemination through radiological and clinical aspects [7]. Current evidence indicates a notable increase in the prevalence and incidence of the disease, and recent studies have suggested a moderate-to-high prevalence in the Middle East region [8]. According to a meta-analysis, however, MS prevalence is low in Saudi Arabia (25/100,000) [8]. The clinical course was relapsing remission in 60.7%, progressive relapse in 20.2%, and primary progression in 19.1%. Weakness, followed by sensory impairment, was the two most common presenting symptoms [8].

In addition to the neurophysiological manifestations of the disease, many psychiatric and physical symptoms, such as fatigue and cognitive issues, may be present, causing increasing burden and suffering to patients and frustrating the identification of depression and anxiety [9,10]. Psychopathological signs and symptoms have been well known since MS was first systematically described [9]. Haussleiter et al. observed a marked memory weakness combined with pathological laughing and weeping, euphoria, mania, hallucinations, and depression [9]. These symptoms can be broadly divided into two categories: mood disorder and neurocognitive disorder. Additionally, indicative treatment of MS will in general focus more on the physical as opposed to the emotional outcome [10]. An estimated one in two people with MS will develop a major depression over the course of their lifetime [11]. A cross-sectional study conducted in Jeddah, Saudi Arabia, showed that depression and anxiety usually affect the patients' employment status and social functioning. More than 50% of the patients reported moderate to severe problems with depression, which indicates that depression negatively correlates with their quality of life [12].

Depression is an important public health problem affecting approximately 350 million people worldwide, gaining ground as the fourth leading cause of disease load [13]. Several chronic diseases were found to be associated with depression. A positive relationship between depression and some chronic diseases has been established in adult populations, especially in the developed countries [13].

Materials and methods

We conducted a cross-sectional study of 365 adult patients affected by MS (132 males and 232 females), selected through a random sampling method from the MS society of Riyadh, Saudi Arabia. We asked participants to complete self-administered questionnaires over a period of four months (from March 2020 to June 2020). We calculated the sample size using the standard Single Proportion Formula at a confidence level of 95%, precision of 5%, and level of significance of 0.05, adding 10% to the original number to compensate for possible losses.

We included participants who were diagnosed with MS, older than 18 years of age, living in Riyadh, had not been diagnosed with psychiatric disease, and were not taking psychotropic medications.

We excluded participants who lived outside of Riyadh city, were known to have psychiatric diseases such as bipolar or schizophrenia, were taking psychotropic or anxiety medications, or did not fill the questionnaire completely.

Prior to data collection, we obtained an IRB approval from King Saud University Research Ethics Committee in Riyadh city, and explained the study objectives to the patients and obtained their voluntary consent before enrolling them in the study.

Questionnaires and scales

We asked patients to complete a self-administered questionnaire that included demographic variables (age, sex, marital status, education, and job), MS clinical features (type, onset, frequency of hospital admission due to relapse, pharmacotherapy, and health status compared to the previous year) and other variables, such as comorbidities and physical health. Patients completed scales, including the Patient Health Questionnaire (PHQ-9) and the Generalized Anxiety Disorder (GAD-7) questionnaire. We used the Arabic validated versions of both questionnaires [14]. The PHQ-9 is a brief, self-administered scale based on the nine Diagnostic and Statistical Manual of Mental Disorder (DSM-IV) criteria of assessing depression, in which a score of 10 is frequently suggested as the cut-off score [15]. The PHQ-9 has a sensitivity of 88% and a specificity of 88% for major depression; as such, it represents an appropriate tool to screen for depression among MS patients [16].

The GAD-7 is a brief, self-administered scale for diagnosing generalized anxiety disorder with a cut-off point of ≥ 10, and has 89% sensitivity and 82% specificity [17]. GAD-7 studies which have adopted this instrument further support its reliability and internal validity for use among MS patients [18].

Statistical analysis

We analyzed the data using the Statistical Package for Social Studies (SPSS v.22; IBM Corp., Armonk, NY, USA). We expressed continuous variables as mean ± standard deviation and categorical variables as percentages. We used the t-test and one-way ANOVA for continuous variables, and the Chi-square test for categorical variables. We considered a p-value of <0.05 statistically significant.

Results

Using the Statistical Package for Social Studies (SPSS v.22; IBM Corp., Armonk, NY, USA), we analyzed the responses from 365 participants through their answers in an online survey targeting MS patients in Riyadh.

Demographic characteristics of the respondents

Respondents were mostly young (52.7%), with females representing twice the number of male participants (63.7%). More than half the respondents were married (58.2%), and most of them had university-level educations (59.9%), and the majority was unemployed (54.9%). Most of the participants responded that they were unaware of their type of MS (54.1%), while most of those who were aware were diagnosed with relapsing multiple sclerosis, the majority had a diagnosis duration of over two years (76.9%), and most reported having had a good to very good general state of health during those years (53.9%) (Table 1).

Table 1. Characteristics of the participants.

    Number (%)
Gender Male 132 36.3
Female 232 63.7
Age 18–25 54 14.8
26–34 138 37.9
35–43 109 29.9
44–52 38 10.4
53–60 19 5.2
60+ 6 1.6
Type of multiple sclerosis Relapsing 120 33.0
Primary progressive 24 6.6
Secondary progressive 23 6.3
Don't know 197 54.1
Duration of diagnosis <2 y 84 23.1
>2 y 280 76.9
Health state in general Bad 16 4.4
Acceptable 84 23.1
Good 80 22.0
Very good 116 31.9
Excellent 68 18.7
Health state in comparison with previous year Much worse than the previous year 15 4.1
Somewhat worse than the previous year 68 18.7
Almost the same 115 31.6
Somewhat better 89 24.5
Much better than the previous year 77 21.2
Educational level Secondary or less 127 34.9
University 218 59.9
Master & PHD 19 5.2
Employment status Free business 15 4.1
Unemployed 200 54.9
Employee full-time 132 36.3
Employee part-time 17 4.7
Social status Single 129 35.4
Married 212 58.2
Widow 3 .8
Divorced 15 4.1
Separated 5 1.4

The results showed that more than half of the participants had moderate or severe anxiety (51.1%) and depression (64%) among community-based MS patients in Riyadh, according to the Generalized Anxiety Disorder (GAD-7) questionnaire Arabic version, while 28.85% of participants showed mild to moderate depression, according to the PHQ-9 Arabic version (Table 2).

Table 2. Prevalence of depression and anxiety among community-based patients with multiple sclerosis.

Disorder Level Number (%)
Anxiety 0–4 minimal anxiety 73 20.1
5–9 mild anxiety 103 28.3
10–14 moderate anxiety 94 25.8
15–21 severe anxiety 92 25.3
Depression 0–4 minimal depression 28 7.7
5–9 mild depression 103 28.3
10–14 moderate depression 107 29.4
15–19 moderately severe depression 71 19.5
20–27 severe depression 55 15.1

Data analysis revealed no significant difference among different types of multiple sclerosis according to the level of anxiety or depression (p = 0.591, 0.288, respectively) (Table 3).

Table 3. Prevalence of depression and anxiety among different types of multiple sclerosis.

    Relapsing Primary progressive Secondary progressive Don't know P-value
Disorder Level Number (%) Number (%) Number (%) Number (%)  
Anxiety 0–4 Minimal anxiety 25 20.83 8 33.33 4 17.39 36 18.46 0.591
5–9 Mild anxiety 36 30.00 3 12.50 8 34.78 56 28.72
10–14 Moderate anxiety 33 27.50 6 25.00 7 30.43 48 24.62
15–21 Severe anxiety 26 21.67 7 29.17 4 17.39 55 28.21
Depression 0–4 Minimal depression 11 9.17 0 0.00 4 17.39 13 6.60
5–9 Mild depression 41 34.17 5 20.83 4 17.39 53 26.90 0.288
10–14 Moderate depression 29 24.17 12 50.00 7 30.43 59 29.95
15–19 Moderately severe depression 23 19.17 3 12.50 5 21.74 40 20.30
20–27 Severe depression 16 13.33 4 16.67 3 13.04 32 16.24

The prevalence of depression and anxiety among different age groups differed significantly; older age groups showed higher levels of mild anxiety (76.32%), compared to younger age groups (60%) (P = 0.007); with depression, results were similar, showing that older age groups had higher levels of depression ranging from mild to moderate depression (53.61%) (P = 0.001), while younger age groups showed moderate to severe anxiety (60.71%) and depression levels (62.32%) (Table 4).

Table 4. Prevalence of depression and anxiety by age group.

Disorder Level Age group
18–25   26–34   35–43   44–52   53–60   60+    
Number (%) Number (%) Number (%) Number (%) Number (%) Number (%) P-value
Anxiety 0–4 Minimal anxiety 8 14.81 31 22.46 17 15.60 6 16.67 8 42.11 3 50.00 0.007*
5–9 Mild anxiety 20 37.04 33 23.91 32 29.36 10 27.78 5 26.32 3 50.00
10–14 Moderate anxiety 14 25.93 48 34.78 22 20.18 9 25.00 1 5.26 0 0.00
15–21 Severe anxiety 12 22.22 26 18.84 38 34.86 11 30.56 5 26.32 0 0.00
Depression 0–4 Minimal depression 5 9.26 9 6.52 6 5.50 3 7.89 1 5.26 4 66.67 0.001*
5–9 mild depression 17 31.48 39 28.26 31 28.44 9 23.68 7 36.84 0 0.00
10–14 Moderate depression 18 33.33 40 28.99 33 30.28 8 21.05 7 36.84 1 16.67
15–19 Moderately severe depression 5 9.26 32 23.19 22 20.18 11 28.95 0 0.00 1 16.67
20–27 Severe depression 9 16.67 18 13.04 17 15.60 7 18.42 4 21.05 0 0.00

The means of depression and anxiety grouped by the characteristics of participants differed significantly for depression, according to health state in general, with bad health status (37.6%) associated with a greater prevalence of depression (P = <0.001) and according to social status, with people who were widowed (22.38%), divorced (26%) and separated (37.82%) associated with significant depression (P = 0.017). For anxiety, there were significant differences according to gender, with females having higher anxiety (54.58%) (P = 0.005). Age also proved significant, with older people showing more anxiety (43.17%) (P = 0.026), and people with a bad general health state (26.38%) associated with higher levels of anxiety (P = <0.001). Other characteristics such as the type of disease, duration of diagnosis, education level, and employment status showed no significant differences (Table 5).

Table 5. Mean of depression and anxiety by characteristics of the participants.

* Significant p value

    Depression Anxiety
Mean SD P-value Mean SD P-value
Gender Male 11.80 6.17 0.109 8.92 5.65 0.005*
Female 12.87 6.09 10.72 5.84
Age 18–25 12.15 6.65 0.166 9.98 5.65 0.026*
26–34 12.47 5.86 9.73 5.57
35–43 12.65 5.97 10.87 5.95
44–52 13.92 6.58 11.17 5.95
53–60 11.32 6.37 7.89 6.72
60+ 7.00 5.02 4.17 1.94
Type of multiple sclerosis Relapsing 11.80 6.06 0.503 9.55 5.36 0.501
Primary progressive 13.17 5.26 9.79 5.76
Secondary progressive 12.43 5.84 9.39 5.25
Don't know 12.81 6.31 10.50 6.17
Duration of diagnosis <2 y 13.32 6.00 0.151 10.50 5.01 0.437
>2 y 12.23 6.16 9.94 6.06
Health state in general Bad 18.31 5.31 <0.001* 14.00 6.88 <0.001*
Acceptable 16.37 5.61 13.42 5.28
Good 13.08 6.28 10.03 6.00
Very good 10.92 5.05 9.31 5.16
Excellent 8.25 4.27 6.34 4.25
Educational level Secondary or less 13.10 5.92 0.246 10.94 6.28 0.072
University 12.25 6.28 9.72 5.43
Masters & PHD 10.95 5.63 8.32 6.65
Employment status Free business 14.07 6.88 0.776 9.33 6.47 0.721
Unemployed 12.43 6.05 10.06 5.79
Employee full-time 12.34 6.19 9.98 5.86
Employee part-time 12.71 6.34 11.53 5.83
Social status Single 12.39 5.86 0.017* 9.71 5.63 0.524
Married 12.15 6.14 10.08 5.89
Widow 13.33 7.23 11.67 7.09
Divorced 15.00 7.00 11.73 6.47
Separate 20.60 3.36 13.00 6.16

Discussion

The association between MS and psychiatric disorders such as depression and anxiety is a complex relationship that has not yet been fully understood [19]. MS is a chronic disease associated with a considerable effect on the patient’s quality of life. Those who suffer from it require physical and psychological care [19]. Our results demonstrate the prevalence level of depression and anxiety among community-based multiple sclerosis patients in Riyadh, in which more than half of the participants had moderate or severe anxiety, while 28.85% of participants showed mild to moderate depression. We also found similar results in a study performed in the UK [20], describing a high frequency of MS patients with mild to moderate depression.

Some early studies have shown that there are differences in the levels of anxiety and depression based on genders and MS types. Anxiety was higher in people with relapsing remitting MS and depression was higher in people with primary progressive MS or secondary progressive MS [20]. There was little correlation between age or disease duration, with higher levels of anxiety in the group aged 15 to 24 years, and higher depression levels in the group aged 45 to 64 years and lower levels in the over 65 years age group [20]. On the other hand, some studies indicate there is no significant correlation between the rates of both disorders and any of the studied variables including duration of the disease, expanded disability status scale, age, gender, and level of education [21].

According to our results, there is no significant difference among different types of multiple sclerosis in terms of the level of anxiety or depression. This view was the opposite of that in a study published in 2012 [20], indicating that female patients with relapsing remitting MS were more anxious than males with this type of MS, and that a female with other types of MS and secondary progressive MS patients were more depressed than other types of MS patients, regardless of gender. Our result showed that most of the participants were unaware of the type of multiple sclerosis they had.

Most of the patients in our study were female and were aged between 26 and 34 years. Most of them were married. A previous study concluded that most MS patients’ relationships with partners, children and close friends were happy and healthy, factors which have an impact on mental health [22]. Being married was associated with a good prognosis in terms of disease progression [23]. These findings are consistent with our findings showing a significant difference in social status, in that people who were widowed, divorced, and separated had significant depressive symptoms.

Most of the participants had college degrees and the majority was unemployed, factors which could cause stress, as disability, gender and employment status exert potentially large effects on quality of life [24]. Furthermore, one report suggested that patients who were unemployed or housewives reported depressive symptoms more frequently than students or employed patients did [20].

An Iranian study demonstrated that depression is significantly associated with fatigue and older age, regardless of other factors. Moreover, most MS patients do not receive adequate treatment, despite the high prevalence of depression in MS [25]. The prevalence of anxiety and depression among MS patients is high and the relationship between economic status and depression and anxiety is significant [26]. In the current study, the prevalence of depression and anxiety differed among different age groups, with the older age groups showing higher levels of both mild anxiety and depression, on average. This finding is not consistent with the results of the previous study [19]. Our study also found a significant relationship between depression and the health state of MS patients, with depression correlating with a deteriorating health status.

Similar to the results of a study performed in 2012, the prevalence of possible depression was high during relapse, reducing gradually post-relapse [27]. Our approach differs from others in the literature since it focuses principally on community-based MS patients; we did not go to hospitals and gather information from there, but rather distributed the survey online for people to answer it, giving us a different perspective on the status of that population.

The limitations of our study

Some of the participants may have forgotten some information - for example, disease type - since their last visit to the doctor, which could have led to some recall bias. The time during which some of the answers were provided was a period of total lockdown in Riyadh city due to the COVID19 situation, which could have affected our results. While our survey was conducted from 25 March 2020 to 23 June 2020, the partial lockdown was implemented from 14 May 2020 to 22 May 2020 and the full lockdown was implemented from 23 May 2020 to 27 May 2020. The majority of the participants did not know what type of MS disorder they had, which could also have affected our results in terms of the correlation between the type of the disease and the anxiety or depression level. The results of the present study need to be evaluated carefully since we did not address the issue of social support and the side-effects of MS medications.

Conclusions

With regard to the prevalence of depression and anxiety among community-based MS patients in Riyadh, our results indicate that more than half of the participants had moderate or severe anxiety (51.1%), while 64% of participants showed moderate or severe depression, and no significant difference in levels of anxiety or depression among different types of MS. Between different age groups, older age groups (aged 53 to over 60 years) reported higher levels of mild anxiety and higher levels of depression, ranging from mild to moderate depression, relative to levels in younger age groups. According to the characteristics of participants, people with a worse health status and differences in social status had a similar tendency for significant deviation towards depression and anxiety, females and middle-aged to older-aged patients deviating more significantly toward anxiety.

Researchers need to consider the type of medication used by patients that may exert deleterious effects on them and cause other side effects, including depression and anxiety, as well as the importance of social support for this group and the need for education of patients regarding various forms of MS, which can also have a significant impact on the quality of their psychosocial well-being.

Acknowledgments

The authors would like to thank Enago (www.enago.com) for the English language review. This research was partially supported in helping us to contact patients by [Arfa Multiple sclerosis society]. We thank our colleagues from [Saed multiple sclerosis organization] who provided insight and expertise that greatly assisted the research.

The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.

The authors have declared that no competing interests exist.

Human Ethics

Consent was obtained by all participants in this study. King Saud University College of Medicine issued approval E-20-5016. 28.06.2020 (07.11.1441) Ref. No. 20/0482/IRB To: Cc: Subject: Study Title: Date of Approval: Date of Expiry: Dr. Ali Mohammed Bahathig Assistant Professor Department of Psychiatry College of Medicine, King Saud University Email: .sa/ Principal Investigator Dr. Mohammed Ahmed Alblowi, Amna Ali Alhilali, Balqees Sami AlJasim, Hamad Mshary Aldakheel, Manal Khalid Alhelow, Nasser Abdulrahman Alodayani, Narjes Hasan Hekry Co-investigators IRB Approval of Research Project No. E-20-5016 “The Prevalence and Association of Depression and Anxiety with Multiple Sclerosis in Riyadh, Saudi Arabia.” 28 June 2020-28 June 2021 Dear Dr. Ali Mohammed Bahathig, I am pleased to inform you that your above-mentioned research project submitted to the IRB was reviewed and approved on 28 June 2020 (07 Dhu Al-Qa’dah 1441). You are now granted permission to conduct this study given that your study does not disclose participant’s identity and poses no risk to the patients. As principal investigator, you are required to abide by the rules and regulations of the Kingdom of Saudi Arabia and the research policies and procedures of the KSU IRB. If you make any changes to the protocol during the period of this approval, you must submit a revised protocol for IRB approval prior to implementing the changes. This approval shall remain valid until the expiry date noted above assuming timely and acceptable responses from the IRB’s periodic requests for surveillance and monitoring information. If you wish to have your protocol approved for continuation, please submit a completed request for reapproval of an approved protocol form (KSU-IRB 017E) at least 30 days before the expiry date. Failure to receive approval for continuation before the expiration date will result in automatic suspension of the approval of this protocol on the expiration date. Information collected following suspension is unapproved research and can never be reported or published as research data. Please quote the project number shown above in any future correspondence or follow-ups related to this study. We wish you success in your research and request you to keep the IRB informed about the progress of the study on a regular basis by submitting a Study Progress Report every 6 months and a Final Report when the study has been completed. Thank you! Sincerely yours, Prof. Abdulrahman AlSultan Chairman of IRB Health Sciences Colleges Research on Human Subjects King Saud University College of Medicine P. O. B ox 7805 Riyadh 11472 K.S.A. Email: .sa

Animal Ethics

Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.

References

  • 1.Chronic illnesses, psychological stress and coping with illnesses. Bengel J, Beutel M, Broda M, et al. Psychother Psychosom Med Psychol. 2003;53:83–93. doi: 10.1055/s-2003-36964. [DOI] [PubMed] [Google Scholar]
  • 2.Multiple sclerosis. Compston A, Coles A. Lancet. 2008;372:1502–1517. doi: 10.1016/S0140-6736(08)61620-7. [DOI] [PubMed] [Google Scholar]
  • 3.The socioeconomic consequences of multiple sclerosis: a controlled national study. Jennum P, Wanscher B, Frederiksen J, Kjellberg J. Eur Neuropsychopharmacol. 2012;22:36–43. doi: 10.1016/j.euroneuro.2011.05.001. [DOI] [PubMed] [Google Scholar]
  • 4.Stress and depression symptoms in patients with multiple sclerosis: the mediating role of the loss of social functioning. Kirchner T, Lara S. Acta Neurol Scand. 2011;123:407–413. doi: 10.1111/j.1600-0404.2010.01422.x. [DOI] [PubMed] [Google Scholar]
  • 5.Natural history of multiple sclerosis symptoms. Kister I, Bacon TE, Chamot E, Salter AR, Cutter GR, Kalina JT, Herbert J. Int J MS Care. 2013;15:146–156. doi: 10.7224/1537-2073.2012-053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Multiple sclerosis: pathology, diagnosis and treatments. Huang WJ, Chen WW, Zhang X. Exp Ther Med. 2017;13:3163–3166. doi: 10.3892/etm.2017.4410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Thompson AJ, Banwell BL, Barkhof F, et al. Lancet Neurol. 2018;17:162–173. doi: 10.1016/S1474-4422(17)30470-2. [DOI] [PubMed] [Google Scholar]
  • 8.Multiple sclerosis epidemiology in Middle East and North Africa: a systematic review and meta-analysis. Heydarpour P, Khoshkish S, Abtahi S, Moradi-Lakeh M, Sahraian MA. Neuroepidemiology. 2015;44:232–244. doi: 10.1159/000431042. [DOI] [PubMed] [Google Scholar]
  • 9.Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment. Haussleiter IS, Brüne M, Juckel G. Ther Adv Neurol Disord. 2009;2:13–29. doi: 10.1177/1756285608100325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Minden SL, Feinstein A, Kalb RC, et al. Neurology. 2014;82:174–181. doi: 10.1212/WNL.0000000000000013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Depression and suicidality in multiple sclerosis: red flags, management strategies, and ethical considerations. Kalb R, Feinstein A, Rohrig A, Sankary L, Willis A. Curr Neurol Neurosci Rep. 2019;19:77. doi: 10.1007/s11910-019-0992-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Quality of life among multiple sclerosis patients in Saudi Arabia. Algahtani HA, Shirah BH, Alzahrani FA, Abobaker HA, Alghanaim NA, Manlangit JS Jr. https://pubmed.ncbi.nlm.nih.gov/29057850/ Neurosciences (Riyadh) 2017;22:261–266. doi: 10.17712/nsj.2017.4.20170273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Epidemiology of anxiety disorders in the 21st century. Bandelow B, Michaelis S. Dialogues Clin Neurosci. 2015;17:327–335. doi: 10.31887/DCNS.2015.17.3/bbandelow. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Health related quality of life measures in Arabic speaking populations: a systematic review on cross-cultural adaptation and measurement properties. Al Sayah F, Ishaque S, Lau D, Johnson JA. Qual Life Res. 2013;22:213–229. doi: 10.1007/s11136-012-0129-3. [DOI] [PubMed] [Google Scholar]
  • 15.The PHQ-9: validity of a brief depression severity measure. Kroenke K, Spitzer RL, Williams JB. J Gen Intern Med. 2001;16:606–613. doi: 10.1046/j.1525-1497.2001.016009606.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Psychometric properties of the PHQ-9 depression scale in people with multiple sclerosis: a systematic review. Patrick S, Connick P. PLoS ONE. 2019;14:197943. doi: 10.1371/journal.pone.0197943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.A brief measure for assessing generalized anxiety disorder: the GAD-7. Spitzer RL, Kroenke K, Williams JB, Löwe B. Arch Intern Med. 2006;166:1092–1097. doi: 10.1001/archinte.166.10.1092. [DOI] [PubMed] [Google Scholar]
  • 18.Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Löwe B, Decker O, Müller S, Brähler E, Schellberg D, Herzog W, Herzberg PY. Med Care. 2008;46:266–274. doi: 10.1097/MLR.0b013e318160d093. [DOI] [PubMed] [Google Scholar]
  • 19.Multiple sclerosis patients in Saudi Arabia: prevalence of depression and its extent of severity. Alhussain H, Aldayel AA, Alenazi A, Alowain F. Cureus. 2020;12:7005. doi: 10.7759/cureus.7005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.A large-scale study of anxiety and depression in people with multiple sclerosis: a survey via the web portal of the UK MS Register. Jones KH, Ford DV, Jones PA, et al. PLoS ONE. 2012;7:41910. doi: 10.1371/journal.pone.0041910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Prevalence of depression and anxiety among patients with multiple sclerosis attending the MS Clinic at Sheikh Khalifa Medical City, UAE: cross-sectional study. Alsaadi T, El Hammasi K, Shahrour TM, et al. Mult Scler Int. 2015;2015:487159. doi: 10.1155/2015/487159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Impact on interpersonal relationships among patients with multiple sclerosis and their partners. Herbert LB, Zerkowski K, O’Brien S, Leonard KV, Bhowmick A. Neurodegener Dis Manag. 2019;9:173–187. doi: 10.2217/nmt-2018-0045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Association of acute stress with multiple sclerosis onset and relapse in Saudi Arabia. AlZahrani AS, Alshamrani FJ, Al-Khamis FA, et al. https://pubmed.ncbi.nlm.nih.gov/30957131/ Saudi Med J. 2019;40:372–378. doi: 10.15537/smj.2019.4.24010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Health-related quality of life in multiple sclerosis: the impact of disability, gender and employment status. Miller A, Dishon S. Qual Life Res. 2006;15:259–271. doi: 10.1007/s11136-005-0891-6. [DOI] [PubMed] [Google Scholar]
  • 25.Prevalence and predictors of depression in Iranian patients with multiple sclerosis: a population-based study. Seyed Saadat SM, Hosseininezhad M, Bakhshayesh B, Seyed Saadat SN, Nabizadeh SP. Neurol Sci. 2014;35:735–740. doi: 10.1007/s10072-013-1593-4. [DOI] [PubMed] [Google Scholar]
  • 26.Prevalence of anxiety, depression, and stress in patients with multiple sclerosis in Kermanshah-Iran: a cross-sectional study. Karimi S, Andayeshgar B, Khatony A. BMC Psychiatry. 2020;20:166. doi: 10.1186/s12888-020-02579-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Multiple sclerosis relapses and depression. Moore P, Hirst C, Harding KE, Clarkson H, Pickersgill TP, Robertson NP. J Psychosom Res. 2012;73:272–276. doi: 10.1016/j.jpsychores.2012.08.004. [DOI] [PubMed] [Google Scholar]

Articles from Cureus are provided here courtesy of Cureus Inc.

RESOURCES